LumaVida operates in a large, growing and structurally under-served market: private women’s healthcare in South Africa. Rising middle-class healthcare spending, growing medical-aid membership among professional women, surging demand for fertility treatment, an ageing female population requiring menopause and preventive care, and a desire for personalised maternity experiences together drive durable demand, against a fragmented supply of specialists and no dominant integrated brand. This section sets out the demand drivers, the supply constraint, and the market’s structure.
Demand, broad, growing and under-served
Demand for specialist women’s health is expanding across the entire lifecycle. Medical-aid membership is growing among professional women; awareness of and demand for fertility treatment is rising sharply; preventive and screening demand (cervical, breast-adjacent, bone and cardiovascular) is increasing; the ageing female population is driving menopause and longevity care; and expectant mothers increasingly seek personalised, premium maternity experiences. Crucially, much of this demand is unmet: only 10–13% of South Africa’s assisted-reproduction need is currently served, a striking indicator of the gap a well-run private platform can address.
Supply — the specialist constraint
The supply of women’s-health specialists is the market’s defining constraint. Obstetrician-gynaecologists are concentrated in the major metros, leaving several provinces under-served, and reproductive-medicine subspecialists are acutely scarce: subspecialty training is available at only two to three centres nationally, with multi-year waiting lists. Because OB/GYNs work across maternity, gynaecology and oncology, few are able to subspecialise in fertility. This shortage both creates the market opportunity, large unmet demand, and defines the central risk, since any operator must itself secure the scarce specialists to deliver.
Key findingThe opportunity and the risk are the same shortage
The under-supply of women’s-health specialists, and fertility subspecialists above all, is exactly why an integrated private platform is needed, and exactly why it is hard to build. The vast unmet demand (only ~10–13% of fertility need met, under-served provinces, growing preventive and menopause demand) underwrites strong volumes for any operator that can deliver care. But the same shortage means LumaVida must win the competition for scarce specialists and leverage each through partnerships, task-sharing and technology. Prospective investors should underwrite the specialist-recruitment plan as rigorously as the financial model.
Service economics and pricing
Women’s-health pricing spans medical-aid tariffs for reimbursed consultations and procedures, private-pay fertility and wellness services, and the recurring membership subscription. The indicative ranges below frame the revenue-per-service economics that underpin the model.
|
Service |
Indicative value |
Payer |
|---|---|---|
|
Specialist consultation |
~R1,000–1,800 |
Medical aid / private |
|
Ultrasound / diagnostics |
~R250–500k per clinic/month |
Medical aid / private |
|
Surgical procedure (partnership share) |
Revenue-share |
Medical aid |
|
Fertility assessment / cycle |
High-value, largely private-pay |
Private / limited medical aid |
|
Wellness membership |
R299 / month |
Subscription (private) |
Market sizing — TAM, SAM, SOM
|
Layer |
Definition |
Indicative scale |
|---|---|---|
|
TAM |
SA private women’s-health spend |
~R30bn per year |
|
SAM |
Medical-aid O&G, fertility & wellness |
~R8bn per year |
|
SOM |
LumaVida at maturity |
~R0.18bn per year |
The sizing is deliberately conservative. A mature nine-clinic network capturing ~R180 million represents a small share of a large, under-served market, leaving substantial headroom for further clinics, services and the regional expansion in the longer-term vision.
The private women’s-health market runs to tens of billions of rand a year across obstetrics, gynaecology, fertility and wellness, and is growing with medical-aid membership and rising demand. A mature nine-clinic LumaVida network capturing ~R180 million represents a small share of a large, under-served market, leaving substantial headroom for the additional clinics, services and the regional expansion in the longer-term vision.